Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
15:44:17 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:CDXC from 2023-04-27 to 2024-04-26 - 28 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-25 08:34U:CDXCNews ReleaseChromaDex Announces Nationwide Launch of Tru Niagen(TM) at The Vitamin Shoppe(TM)
2024-04-24 08:34U:CDXCNews ReleaseChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
2024-04-23 08:32U:CDXCNews ReleaseChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen(TM) at Sprouts Farmers Market
2024-03-26 08:32U:CDXCNews ReleaseChromaDex Announces Tru Niagen(TM) is Now Third-Party Verified Through the Alkemist Assured(TM) Transparency Program
2024-03-06 16:04U:CDXCNews ReleaseChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
2024-02-21 08:32U:CDXCNews ReleaseChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
2024-01-26 16:08U:CDXCNews ReleaseChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
2023-12-20 09:04U:CDXCNews ReleaseChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen ‚ ®
2023-12-12 10:30U:CDXCNews ReleaseNeurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+
2023-11-30 08:34U:CDXCNews ReleaseA Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen ‚ ®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)
2023-11-15 08:32U:CDXCNews ReleaseNewly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen ‚ ®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients
2023-11-09 08:32U:CDXCNews ReleaseChromaDex to Participate in Renmark ¢ € ™s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023
2023-11-08 16:02U:CDXCNews ReleaseChromaDex Corporation Reports Third Quarter 2023 Financial Results
2023-11-01 08:34U:CDXCNews ReleaseChromaDex Debuts Clinical Strength Tru Niagen ‚ ® Pro 1,000mg Featuring Niagen ‚ ® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide
2023-10-31 08:34U:CDXCNews ReleaseChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
2023-10-26 08:32U:CDXCNews ReleaseChromaDex and Zesty Paws ‚ ® Crack the Code on Cellular Health for Dogs With ¢ € ˜Healthy Aging ¢ € ™ Line
2023-10-02 08:32U:CDXCNews ReleaseA Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients
2023-08-24 08:32U:CDXCNews ReleasePreclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN
2023-08-09 16:02U:CDXCNews ReleaseChromaDex Corporation Reports Second Quarter 2023 Financial Results
2023-08-08 08:34U:CDXCNews ReleaseChromaDex Launches Tru Niagen ‚ ® with iHerb, the World ¢ € ™s Number One Online Destination for Health and Wellness
2023-08-07 08:32U:CDXCNews ReleaseChromaDex to Participate in Renmark ¢ € ™s Virtual Non-Deal Roadshow Series
2023-08-02 08:02U:CDXCNews ReleaseChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
2023-07-18 08:32U:CDXCNews ReleaseFindings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects
2023-06-16 08:32U:CDXCNews ReleaseChromaDex, a Global Authority on Nicotinamide Adenine Dinucleotide (NAD+), Celebrates the 10th Anniversary of its ChromaDex External Research Program (CERP ¢ „ ¢), the Industry Leading Research Program Advancing the Science of NAD+ and Healthy Aging
2023-05-30 08:34U:CDXCNews ReleaseChromaDex to Participate in the LD Micro Invitational XIII
2023-05-11 08:34U:CDXCNews ReleaseChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference
2023-05-10 16:02U:CDXCNews ReleaseChromaDex Corporation Reports First Quarter 2023 Financial Results
2023-05-02 08:32U:CDXCNews ReleaseChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023